Join Neuralink's Patient Registry

We are committed to developing devices to restore autonomy to those with unmet medical needs with input from the communities and individuals we aim to serve. The Patient Registry allows us to connect with and understand the needs of a diverse group of individuals with various conditions. The Patient Registry also helps us determine your preliminary eligibility for current and/or future Neuralink clinical trials.

Anyone within Canada who is at least 18 years old and the age of majority in their province/territory, who is able to consent, and who has quadriplegia, paraplegia, vision loss, hearing loss, the inability to speak, and/or major limb amputation (affecting above or below the elbow and/or above or below the knee), is invited to participate in the Patient Registry.

While there is no direct benefit from participating in the Patient Registry, your participation will support research that may benefit society and/or others with similar medical conditions. If you submit a completed Patient Registry application, we may also contact you or your legally authorized representative about your eligibility for current and/or future Neuralink clinical trials.

We will ask about current and past medical information, demographics, education, work, and the assistive technologies you use. To participate in the Patient Registry, we will ask for your medical records. If you have a legally authorized representative, we will ask for their contact information.

We will not sell the personal information you provide to any third party. We may share such personal information with Neuralink’s affiliates, third parties, and research partners acting on behalf of Neuralink. The information you provide may be used to determine your potential eligibility for current and/or future Neuralink clinical trials as well as for research purposes and potential product development. Your contact information may also be used to communicate with you (or your legally authorized representative) about your Patient Registry application, Neuralink, Neuralink clinical trials, or Neuralink’s technology. If required, we may also share information you provide with regulatory agencies, such as an institutional review board (IRB), to comply with Neuralink’s regulatory obligations or to comply with the law. Only authorized Neuralink personnel with the appropriate privacy and confidentiality training and authorized third parties will be able to access the identifiable personal information you provide. We may create de-identified data from the personal information you provide by excluding information that personally identifies you. We may use this de-identified data for internal research and product development, or any other legal purpose.

We may use the information you provide to determine your preliminary eligibility for current and/or future Neuralink clinical trials. Participation in the Patient Registry is however not a prerequisite or sufficient for later participation in a Neuralink clinical trial. You will not be considered enrolled into any Neuralink clinical trials and/or research study by participating in the Patient Registry. You will be asked to review and sign a separate informed consent document before participating in any current and/or future Neuralink clinical trial.

The PRIME Study (short for Precise Robotically Implanted Brain-Computer Interface) – a groundbreaking investigational medical device trial for our fully-implantable, wireless brain-computer interface (BCI) – aims to evaluate the safety of our implant (N1) and surgical robot (R1) and assess the initial functionality of our BCI for enabling people with quadriplegia to control external devices with their thoughts.

We are excited to announce that recruitment is now open for the Canadian PRIME Study (CAN-PRIME), which will be conducted in collaboration with our partner hospitals in Canada.

This research may help us find safer, more effective ways to implant and use our BCI to potentially restore and enhance computer control and other capabilities.

If you have limited or no ability to use both hands due to cervical spinal cord injury or amyotrophic lateral sclerosis (ALS), you may qualify for the CAN-PRIME Study.

If you're interested in learning whether you may qualify for current and/or future Neuralink clinical trials, consider joining our Patient Registry.

Upon providing your consent to participate in the Patient Registry, you have the right to withdraw your consent at any time by contacting us at patientregistry@neuralink.com. Upon receiving your withdrawal request, Neuralink will stop any further collection and use of your data (e.g., obtaining authorized medical records) as soon as reasonably possible, and will delete your records from the Patient Registry within 90 business days of receipt of such request. Upon receipt of your withdrawal request, Neuralink will also request that third parties with whom it shared your personal information stop using such information and delete such information in a reasonable timeframe. While your withdrawal will be effective upon receipt by Neuralink, it will not be effective to the extent that Neuralink or others have already relied upon this consent, which means that any processing of your data prior to the receipt of your withdrawal request cannot be undone.